Streetbeat News

AUPH

Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Industry

Biotechnology

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Open

9.65

Mkt cap

1.3B

Volume

1.3M

High

9.69

P/E Ratio

-62.47

52-wk high

10.67

Low

9.22

Div yield

N/A

52-wk low

4.71

Aurinia Pharmaceuticals Inc. has posted strong Q3 results and announced cost reduction measures. The company is experiencing impressive sales growth, has a strong balance sheet, and is expected to become more profitable in the future. There is speculation about a potential buyout.

Portfolio Pulse from

November 08, 2024 | 5:30 pm

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) held its Q3 2024 earnings call on November 7, 2024. Key participants included Andrea Christopher, Peter Greenleaf, Greg Keenan, and Joe Miller. Analysts from TD Cowen, Jefferies, Cantor Fitzgerald, and Leerink Partners participated.

Portfolio Pulse from

November 07, 2024 | 5:00 pm

Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.10 per share, surpassing the Zacks Consensus Estimate of $0.02 per share. This marks a significant improvement from a loss of $0.09 per share a year ago.

Portfolio Pulse from

November 07, 2024 | 2:00 pm

Aurinia Pharmaceuticals will present six abstracts, including five poster presentations, at the American Society Of Nephrology Kidney Week 2024. The presentations will focus on LUPKYNIS® (voclosporin), a treatment for lupus nephritis, highlighting its clinical importance and real-world effectiveness.